Ab­b­Vie part­ners on an Op­di­vo com­bo study with Bris­tol-My­ers; In­ter­cept tum­bles on FDA warn­ing

⇨ Ab­b­Vie wants to ex­plore how a com­bi­na­tion of its an­ti-c-Met an­ti­body drug AB­BV-399 will work in com­bi­na­tion with Bris­tol-My­ers’ Op­di­vo in treat­ing non-small cell lung can­cer. This is the lat­est in hun­dreds of com­bo stud­ies with check­point drugs, and Ab­b­Vie is tak­ing the lead on ex­e­cut­ing the Phase Ib study.

⇨ Shares of In­ter­cept Phar­ma­ceu­ti­cals $ICPT tum­bled bad­ly af­ter the FDA is­sued a warn­ing about the risk of death and in­jury pa­tients face tak­ing their drug Ocali­va. Some an­a­lysts spec­u­late that the FDA may be about to slap a black box warn­ing on the drug — sold for pri­ma­ry bil­iary cholan­gi­tis — that could crimp sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER